Log-in
Sign-up
Webcast
Clinical Trials
Library
Webcast
Clinical Trials
Library
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
TERMINATED
NCT03505710
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
181
Enrollment(s)
21
Study location(s)
INTERVENTIONAL (PHASE2)
Non-Small Cell Lung Cancer
RECRUITING
NCT06809764
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
150
Enrollment(s)
23
Study location(s)
OBSERVATIONAL (None)
Non-small Cell Lung Cancer
TERMINATED
NCT05066789
CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4
100
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Artery Disease
ACTIVE_NOT_RECRUITING
NCT03129490
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
11,000
Enrollment(s)
38
Study location(s)
INTERVENTIONAL (PHASE4)
Atrial Fibrillation
Atrial Flutter
ACTIVE_NOT_RECRUITING
NCT03129555
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
5,000
Enrollment(s)
26
Study location(s)
INTERVENTIONAL (PHASE4)
Deep Vein Thrombosis
Pulmonary Embolism
RECRUITING
NCT06957366
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
920
Enrollment(s)
14
Study location(s)
INTERVENTIONAL (NA)
Atrial Fibrillation (AF)
VTE
ACTIVE_NOT_RECRUITING
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
1,600
Enrollment(s)
481
Study location(s)
INTERVENTIONAL (PHASE3)
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
TERMINATED
NCT06231693
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
2
Enrollment(s)
2
Study location(s)
OBSERVATIONAL (None)
Breast Cancer
16
17
18
19
20